Senti Biosciences, Inc. ( (SNTI) ) has released its Q4 earnings. Here is a breakdown of the information Senti Biosciences, Inc. presented to its investors.
Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative cell and gene therapies using its proprietary Gene Circuit platform, with a primary focus on oncology.
In its latest earnings report, Senti Bio highlighted significant progress in its SENTI-202 program and strengthened its financial position through a successful private investment in public equity (PIPE) financing. The company also expanded its leadership team and board of directors, positioning itself for future growth.
Key financial metrics from the report include a net loss of $0.6 million for the fourth quarter of 2024, a decrease in research and development expenses to $7.8 million, and general and administrative expenses of $8.4 million. The company raised $47.6 million through PIPE financing, which is expected to extend its financial runway into 2026. Additionally, Senti Bio received $1.5 million from a CIRM grant to support the clinical development of SENTI-202.
The company’s SENTI-202 program showed promising results in its Phase 1 clinical trial, with two out of three AML patients achieving complete remission. The trial demonstrated that SENTI-202 was generally well-tolerated, and the company plans to continue sharing data as the trial progresses.
Looking ahead, Senti Bio remains optimistic about the potential of its Gene Circuit platform and its ability to advance next-generation cell therapies in oncology. The company is committed to furthering its research and development efforts and leveraging its strengthened financial position to drive future growth.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com